Santhera Pharmaceuticals Holding AG (Santhera Pharmaceuticals Holding AG) Debt-to-Equity : -0.97 (As of Jun. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Santhera Pharmaceuticals Holding AG Debt-to-Equity?

Santhera Pharmaceuticals Holding AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $24.42 Mil. Santhera Pharmaceuticals Holding AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $21.68 Mil. Santhera Pharmaceuticals Holding AG's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $-47.49 Mil. Santhera Pharmaceuticals Holding AG's debt to equity for the quarter that ended in Jun. 2023 was -0.97.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Santhera Pharmaceuticals Holding AG's Debt-to-Equity or its related term are showing as below:

SPHDF' s Debt-to-Equity Range Over the Past 10 Years
Min: -11.2 Med: 1.96 Max: 293.53
Current: -0.97

During the past 13 years, the highest Debt-to-Equity Ratio of Santhera Pharmaceuticals Holding AG was 293.53. The lowest was -11.20. And the median was 1.96.

SPHDF's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs SPHDF: -0.97

Santhera Pharmaceuticals Holding AG Debt-to-Equity Historical Data

The historical data trend for Santhera Pharmaceuticals Holding AG's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santhera Pharmaceuticals Holding AG Debt-to-Equity Chart

Santhera Pharmaceuticals Holding AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

1.96

2.82

-11.20

32.36

-1.02

Santhera Pharmaceuticals Holding AG Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Equity	Get a 7-Day Free Trial															5.19	32.36	-2.94	-1.02	-0.97

Competitive Comparison of Santhera Pharmaceuticals Holding AG's Debt-to-Equity

For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Santhera Pharmaceuticals Holding AG's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Santhera Pharmaceuticals Holding AG's Debt-to-Equity falls into.

Santhera Pharmaceuticals Holding AG Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Santhera Pharmaceuticals Holding AG's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(24.42	+	23.279)	/	-46.894
	=	-1.02

Santhera Pharmaceuticals Holding AG's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(24.419	+	21.679)	/	-47.492
	=	-0.97

Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Santhera Pharmaceuticals Holding AG Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Santhera Pharmaceuticals Holding AG's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Santhera Pharmaceuticals Holding AG (Santhera Pharmaceuticals Holding AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

SANNz:UK SANN:Switzerland

Address

Hohenrainstrasse 24, Pratteln, CHE, 4133

Website

https://www.santhera.com

Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives most of its revenue from the European Union.